论文部分内容阅读
目的研究尼非卡兰对心房及肺静脉组织动作电位的影响,探讨尼非卡兰在房性心律失常中的作用。方法2006年3月至4月,阜外心血管病医院电生理中心及北京市朝阳医院心脏中心从15只大耳白兔取右心房、左心房和肺静脉组织制成0.5cm×1.5cm组织条,用2倍阈强度,脉宽3ms刺激引发动作电位,采用标准玻璃微电极技术记录心房及肺静脉肌袖组织动作电位,用分级递增刺激和程序刺激测定各部位组织在基础条件下的不应期。用质量浓度为2.13mg/L的尼非卡兰的台氏液灌流组织条15min后,采用同样方法引发动作电位和测定不应期,比较用尼非卡兰前后动作电位时相和不应期的变化。结果尼非卡兰灌流后,左心房APD90由(51±16)ms延长到(78±33)ms(P<0.05),右心房APD90由(53±12)ms延长到(71±13)ms(P<0.05,),肺静脉肌袖APD90由(59±7)ms延长到(98±11)ms(P<0.001,),ERP由(102±8)ms延长到(118±13)ms(P<0.05)。结论尼非卡兰的延长心房和肺静脉肌袖组织动作电位时相及不应期的电药理作用可能是其治疗房性心律失常的基础。
Objective To study the effects of nifedialpha on the action potentials of atrial and pulmonary venous tissue and to explore the role of nifedial in the atrial arrhythmia. Methods From March 2006 to April 2006, the electrophysiological center of Fu Wai Hospital and the heart center of Chaoyang Hospital of Beijing made 0.5cm × 1.5cm tissue strips from the right atrium, left atrium and pulmonary vein of 15 rabbits , And the action potentials were induced by 2 times threshold intensity and pulse duration of 3 ms. The action potentials of atrium and pulmonary vein muscular sleeves were recorded by standard glass microelectrode technique. The increments and procedural stimuli were recorded to determine the refractory period . With the concentration of 2.13mg / L of nifeducin in Tissue perfusion of tissue strips after 15min, using the same method to trigger action potentials and determination of refractory period, compared with before and after the action of niacaplatin phase and refractory period The change. Results APD90 in the left atrium was prolonged from (51 ± 16) ms to (78 ± 33) ms (P <0.05), while the right atrium APD90 was prolonged from (53 ± 12) ms to (71 ± 13) ms (P <0.05). The APD90 of the pulmonary vein sleeve was prolonged from (59 ± 7) ms to (98 ± 11) ms (P <0.001) and ERP was prolonged from (102 ± 8) ms to (118 ± 13) ms P <0.05). CONCLUSION: The pharmacodynamic effects of nifedial in prolonging the action potentials of atrial and pulmonary venous sleeves during the phase and refractory period may be the basis of its treatment for atrial arrhythmias.